KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Elanco Animal Health (ELAN) Receivables (2017 - 2026)

Elanco Animal Health's Receivables history spans 9 years, with the latest figure at $940.0 million for Q4 2025.

  • On a quarterly basis, Receivables rose 6.09% to $940.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $940.0 million, a 6.09% increase, with the full-year FY2025 number at $940.0 million, up 6.09% from a year prior.
  • Receivables hit $940.0 million in Q4 2025 for Elanco Animal Health, down from $975.0 million in the prior quarter.
  • Over the last five years, Receivables for ELAN hit a ceiling of $1.3 billion in Q1 2023 and a floor of $886.0 million in Q4 2024.
  • Historically, Receivables has averaged $1.1 billion across 5 years, with a median of $1.1 billion in 2024.
  • Biggest five-year swings in Receivables: soared 120.26% in 2021 and later decreased 20.35% in 2024.
  • Tracing ELAN's Receivables over 5 years: stood at $1.0 billion in 2021, then decreased by 2.53% to $1.0 billion in 2022, then grew by 0.8% to $1.0 billion in 2023, then fell by 12.28% to $886.0 million in 2024, then rose by 6.09% to $940.0 million in 2025.
  • Business Quant data shows Receivables for ELAN at $940.0 million in Q4 2025, $975.0 million in Q3 2025, and $1.1 billion in Q2 2025.